Boehringer Ingelheim Venture Fund followed an investment last September by contributing to a $26.8m round for the Basel spinout.

The CNS disease therapy developer raised a further $20m, adding to a $45m close in April that included GV and Takeda Ventures.

UPMC Enterprises has contributed to a $20m series B extension for Cerevance, which is commercialising Rockefeller University research.

Septwolves Ventures participated in a $21.5m round for the X-ray equipment producer that was led by a China Construction Bank fund.

Boehringer Ingelheim Venture Fund followed an investment last September by contributing to a $26.8m round for the bacteria-based cancer drug developer.

Santen Ventures co-led a series B round to bring TAU faculty-founded Belkin Laser's funding total to $16.3m.

Santen Ventures co-led a series B round also backed by C-Mer Eye Care and BioLight Life Science to bring Belkin Laser's funding total to $16.3m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.

Fidelity led a series C round for haematology and cancer therapy developer Antengene, whose corporate shareholders include Celgene, Taikang, Tigermed and WuXi AppTec.